Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;31(9):7012-7021.
doi: 10.1007/s00330-021-07841-w. Epub 2021 Mar 13.

[18F]FDG PET/CT quantitative parameters for the prediction of histological response to induction chemotherapy and clinical outcome in patients with localised bone and soft-tissue Ewing sarcoma

Alessio Annovazzi  1 , Virginia Ferraresi  2   3 , Vincenzo Anelli  4 , Renato Covello  5 , Sabrina Vari  2 , Carmine Zoccali  6 , Roberto Biagini  6 , Rosa Sciuto  7
Affiliations

[18F]FDG PET/CT quantitative parameters for the prediction of histological response to induction chemotherapy and clinical outcome in patients with localised bone and soft-tissue Ewing sarcoma

Alessio Annovazzi et al. Eur Radiol. 2021 Sep.

Abstract

Objective: The application of [18F]FDG PET/CT in predicting histologic response to induction chemotherapy in patients with Ewing sarcoma (EWS) has been proposed using the values of pre-post treatment SUVmax as a referral parameter, although with heterogeneous results. The aim of this retrospective study was to evaluate the diagnostic accuracy of [18F]FDG PET/CT volumetric parameters (metabolic tumour volume (MTV) and total lesion glycolysis (TLG)) as compared to SUVmax to predict response to chemotherapy and clinical outcome in patients with localised EWS of bone and soft-tissue.

Methods: Twenty-eight patients with non-metastatic EWS of bone (n = 20) and soft tissues (n = 8) who underwent a [18F]FDG PET/CT scan before (PET1) and after induction chemotherapy (PET2) were enclosed in the analysis. Values of PET metrics (SUVmax, MTV, TLG) at diagnosis and after neoadjuvant chemotherapy as well as the percentage change between PET1 and PET2 (ΔSUV, ΔMTV and ΔTLG) were correlated to histological response and to progression-free survival (PFS).

Results: ΔTLG (cut-off: -60%) is the best predictor for histologic response with 100% sensitivity and 77.8% specificity. MTV1 > 33.4 cm3 and TLG1 > 112 were also associated with a favourable histologic response (sensitivity 80% and specificity 77.8% for both). On multivariate analysis, SUV2 (> 3.3) and ΔTLG (< -18%) were independent predictors of worse PFS.

Conclusions: [18F]FDG PET/CT could accurately predict histologic response to neoadjuvant chemotherapy in patients with EWS, also showing a possible prognostic value for future disease relapse.

Key points: • The variation of the PET parameter tumour lesion glycolysis (TLG) can predict the histologic response to induction chemotherapy (sensitivity 100%, specificity 77.8%), in patients with Ewing sarcoma. • The percentage variation of TLG and the value of the SUVmax at PET scan after chemotherapy show a prognostic role for future disease relapse. The combination of both the parameters identifies three prognostic classes of patients with low, intermediate and high risk of disease relapse.

Keywords: Ewing sarcoma; Fluorine-18-fluorodeoxyglucose; Induction chemotherapy; PET/CT scan; Patient outcome assessment.

PubMed Disclaimer

References

    1. Gaspar N, Hawkins DS, Dirksen U et al (2015) Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol 33:3036–3046. https://doi.org/10.1200/JCO.2014.59.5256 - DOI - PubMed
    1. Ozaki T, Hillmann A, Hoffmann C et al (1996) Significance of surgical margin on the prognosis of patients with Ewing’s sarcoma. A report from the Cooperative Ewing’s Sarcoma Study. Cancer 78:892–900. https://doi.org/10.1002/(SICI)1097-0142(19960815)78:4<892::AID-CNCR29... - DOI - PubMed
    1. Grünewald TGP, Cidre-Aranaz F, Surdez D et al (2018) Ewing sarcoma. Nat Rev Dis Primers 4:5. https://doi.org/10.1038/s41572-018-0003-x - DOI - PubMed
    1. Bacci G, Ferrari S, Longhi A et al (2003) Therapy and survival after recurrence of Ewing’s tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol 14:1654–1659. https://doi.org/10.1093/annonc/mdg457 - DOI - PubMed
    1. Stahl M, Ranft A, Paulussen M et al (2011) Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 57:549–553. https://doi.org/10.1002/pbc.23040 - DOI - PubMed

Substances

LinkOut - more resources